BMS Ends Cellares Partnership Over Production Failures, Triggering ~100 Layoffs
NewsData.io · United States · Aug 26, 2026
Bristol Myers Squibb has terminated its $380 million capacity agreement with cell therapy manufacturer Cellares after determining the company's Cell Shuttle system could not meet requirements for commercial production of CAR-T therapy Breyanzi. Cellares will lay off approximately 100 employees on October 20, per a California WARN Act filing, affecting roles across engineering, marketing, recruitment, and software. The cuts come just 10 months after Cellares raised $257 million to scale toward commercial production. The layoffs signal continued volatility in the CDMO/cell therapy manufacturing sector, with ripple effects for specialized biotech talent demand.
Get the weekly brief by email
What changed in staffing last week, every Monday morning. Free. Unsubscribe anytime.
Related stories
Detroit ABC affiliate WXYZ-TV (Channel 7) has eliminated at least 30 positions through a combination of buyouts and layoffs, according to sources who…
Dole Packaged Foods will permanently close its Atwater, California processing facility and a nearby Livingston laboratory, eliminating 404 jobs in…
About 1,400 IRS IT employees displaced by DOGE-directed downsizing have been reorganized into 'ONE IRS Readiness' teams with no defined mission…
Lufthansa plans to eliminate 1,000 full-time positions at its flagship carrier, with reductions targeted at its Frankfurt and Munich hubs…